4,4,5,5-tetramethyloxazolidin-2-one | 52856-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 4,4,5,5-tetramethyloxazolidin-2-one
• 英文别名: 4,4,5,5-Tetramethyl-1,3-oxazolidin-2-one
• CAS: 52856-03-8
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: QULBHIBEAZTUQA-UHFFFAOYSA-N

物化性质

• 沸点：
  260.6±7.0 °C(Predicted)
• 密度：
  0.960±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4,5,5-tetramethyloxazolidin-2-one 在 sodium hydride 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 22.0h， 生成 (S)-3-(2-((1-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)ethyl)amino)-5-fluoropyrimidin-4-yl)-4,4,5,5-tetramethyloxazolidin-2-one
  参考文献：
  名称：

  口服生物利用度和脑渗透突变IDH1抑制剂3-嘧啶-4-基-恶唑烷-2-酮的优化

  摘要：

  突变异柠檬酸脱氢酶1（IDH1）是治疗各种癌症（例如AML，神经胶质瘤和胶质母细胞瘤）的有吸引力的治疗靶标。我们已经评估了3-pyrimidin-4-yl-oxazolidin-2-ones作为与IDH1 R132H的变构，诱导口袋结合的突变IDH1抑制剂。这封信描述了针对改善化合物的体外和体内代谢稳定性的SAR探索，从而将19鉴定为有效的和选择性的突变IDH1抑制剂，该IDH1抑制剂已证明在啮齿动物中具有大脑渗透性和出色的口服生物利用度。在临床前患者衍生的IDH1突变异种移植肿瘤模型研究中，19 有效地抑制了生物标记物2-HG的产生。

  DOI：

  10.1021/acsmedchemlett.8b00182
• 作为产物：
  描述：

  2,2,3-三甲基-1,3-丁二醇 在 sodium azide 、 (二氯碘)-苯 作用下， 以 乙酸乙酯 为溶剂， 反应 12.0h， 以81%的产率得到4,4,5,5-tetramethyloxazolidin-2-one
  参考文献：
  名称：

  使用二氯化碘苯和叠氮化钠直接由1,3-二元醇或3-氨基醇直接合成恶唑烷酮-2-酮和咪唑啉酮-2-酮

  摘要：

  使用碘代二氯二苯甲烷（PhICl 2）和叠氮化钠的相同试剂组合，开发了一种直接，直接由1,3-二醇和3-氨基醇合成恶唑烷-2-酮和咪唑啉-2-酮的通用有效方法。（NaN 3）。

  DOI：

  10.1002/adsc.201300982

文献信息

• MAX BINDERS AS MYC MODULATORS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20170233405A1

  公开（公告）日：2017-08-17

  The present disclosure provides compounds of Formula (I′), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits.

  本公开提供了Formula (I′)、Formula (I)、Formula (II)、Formula (II-A)、Formula (III)和Formula (IV)的化合物。本文描述的化合物是MAX结合蛋白和/或Myc、Mad或Mxi1的调节剂（例如，Myc、Mad或Mxi1的抑制剂），可能在治疗与Myc相关的疾病的患者中有用，例如增殖性疾病（例如癌症）。本公开还提供了包括上述化合物的药物组合物和试剂盒，以及使用这些化合物、组合物和试剂盒的方法和用途。
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：VESTAS WIND SYSTEMS A/S

  公开号：US20140235620A1

  公开（公告）日：2014-08-21

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 -R 6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式（I）的化合物或其药用盐，其中R1-R6在此处定义。该发明还涉及含有公式（I）化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式（I）的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• [EN] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH<br/>[FR] 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES COMME INHIBITEURS D'IDH MUTANTE
  申请人：NOVARTIS AG

  公开号：WO2013046136A1

  公开（公告）日：2013-04-04

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formual (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  该发明涉及公式(I)的化合物或其药学上可接受的盐，其中R1-R6在此处被定义。该发明还涉及含有公式(I)化合物的组合物，以及利用这些化合物抑制具有新型活性的突变IDH蛋白。该发明还涉及利用公式(I)的化合物治疗与这些突变IDH蛋白相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。
• Heterocyclic compounds and their production
  申请人：Sumitomo Pharmaceuticals Company, Limited

  公开号：US05231179A1

  公开（公告）日：1993-07-27

  A compound of the formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom, a lower alkyl group, an ar(lower)alkyl group or an aryl group, or R.sub.1 and R.sub.2 may be combined together to form a lower alkylene group and/or R.sub.3 and R.sub.4 are combined together to form a lower alkylene group, or R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may be combined together to form an o-phenylene group, X is a halogen atom and Y is an oxygen atom or a nitrogen atom substituted with lower alkyl or aryl, which is useful as an intermediate in the synthesis of 1.beta.-methylcarbapenem compounds valuable as antibiotics.

  其中R.sub.1、R.sub.2、R.sub.3和R.sub.4分别是氢原子、较低的烷基基团、取代芳基烷基基团或芳基，或者R.sub.1和R.sub.2可以结合形成较低的烷基烯基基团和/或R.sub.3和R.sub.4结合形成较低的烷基烯基基团，或者R.sub.1、R.sub.2、R.sub.3和R.sub.4可以结合形成o-苯基烯基基团，X是卤素原子，Y是氧原子或取代较低烷基或芳基的氮原子，这在1-β-甲基卡巴比那酮类抗生素的合成中作为中间体是有用的。
• 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
  申请人：Caferro Thomas Raymond

  公开号：US08957068B2

  公开（公告）日：2015-02-17

  The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中R1-R6在此定义。本发明还涉及含有式（I）的化合物的组合物，并且涉及使用这种化合物来抑制具有新型活性的突变IDH蛋白质。本发明还涉及使用式（I）的化合物来治疗与这种突变IDH蛋白质相关的疾病或紊乱，包括但不限于细胞增殖紊乱，如癌症。